atai Life Sciences
Update in progressATAI (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing mental health therapies in the U.S., Germany, and Canada. It advances programs such as BPL-003, an intranasal form of the benzoate salt of mebufotenin, for treatment-resistant depression and alcohol use disorder; RL-007 for cognitive impairment in schizophrenia; ELE-101 for major depressive disorder; and VLS-01, an oral transmucosal DMT for TRD. It also pursues EMP-01 for social anxiety, EGX-A/B for TRD, COMP360 psilocybin therapy, and GRX-917 for anxiety, depression, and neurological disorders. Formerly Atai Beckley N.V., it renamed to AtaiBeckley Inc. in 2025. Founded in 2018, based in New York.
Company score
- Sentiment
- 0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.32
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.28
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!